Sun Pharmaceutical vs Cipla: share price, P/E, ROE and financials compared
Sun Pharmaceutical Industries
Cipla
Sun Pharmaceutical and Cipla at a glance
Sun Pharmaceutical and Cipla are both listed in Healthcare. Sun Pharmaceutical is the larger by market cap, at ₹4.5L Cr against ₹1.1L Cr for Cipla (3.9 times as large). On valuation, Cipla has the lower P/E (39.4× against 40.7×) and the lower price-to-book (3.22× against 4.99×). On returns and margins, Sun Pharmaceutical has the higher ROCE (17.9% against 14.9%), the higher ROE (13.1% against 8.3%) and the higher operating margin (28.2% against 17.3%). Over three years, Sun Pharmaceutical has faster 3-year sales growth (+10.4% against +7.2% a year), while Cipla has faster 3-year profit growth (+11.5% against +10.6% a year). Neither carries much debt for its equity: debt-to-equity is 0.04× for Sun Pharmaceutical and 0.02× for Cipla.
Key metrics, side by side
| Metric | Sun PharmaceuticalSUNPHARMA | CiplaCIPLA |
|---|---|---|
| Price (₹) | 1,860.00 | 1,411.00 |
| Market cap (₹ Cr) | 4,46,276 | 1,13,993 |
| P/E | 40.7× | 39.4× (the lower figure, shaded) |
| P/B | 4.99× | 3.22× (the lower figure, shaded) |
| Dividend yield, trailing | 0.86% | 0.92% |
| ROE | 13.1% (the higher figure, shaded) | 8.3% |
| ROCE | 17.9% (the higher figure, shaded) | 14.9% |
| Operating margin (OPM) | 28.2% (the higher figure, shaded) | 17.3% |
| Net margin (NPM) | 17.8% (the higher figure, shaded) | 10.4% |
| Sales CAGR 3Y | +10.4% (the higher figure, shaded) | +7.2% |
| Profit CAGR 3Y | +10.6% | +11.5% (the higher figure, shaded) |
| Debt to equity | 0.04× | 0.02× |
| Interest cover | 45.6× | 109.3× (the higher figure, shaded) |
| Net profit TTM (₹ Cr) | 10,966 | 2,897 |
| 1Y return | +8.2% (the higher figure, shaded) | −6.6% |
| Promoter holding | 52.68% | 29.21% |
Sun Pharmaceutical vs Cipla: common questions
Which is bigger, Sun Pharmaceutical or Cipla?
By market cap, Sun Pharmaceutical is bigger at ₹4.5L Cr, against ₹1.1L Cr for Cipla (prices as of 6 Nov 2026). Net profit over the last twelve months was ₹10,966 Cr for Sun Pharmaceutical and ₹2,897 Cr for Cipla.
Which has a lower P/E ratio, Sun Pharmaceutical or Cipla?
Sun Pharmaceutical trades at a P/E of 40.7× and Cipla at 39.4×. Cipla has the lower P/E. P/E is the share price divided by earnings per share; it varies a lot between industries and with growth, so it says little on its own.
Which has a higher ROE, Sun Pharmaceutical or Cipla?
Sun Pharmaceutical reports a return on equity of 13.1% and Cipla 8.3%. Sun Pharmaceutical has the higher ROE. ROE is net profit as a share of shareholders’ equity.
Which is growing faster, Sun Pharmaceutical or Cipla?
Over the last three years: Sales grew +10.4% a year at Sun Pharmaceutical and +7.2% at Cipla, so Sun Pharmaceutical grew sales faster; profit grew +10.6% a year at Sun Pharmaceutical and +11.5% at Cipla, so Cipla grew profit faster. Past growth doesn’t predict future growth.